Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
15764 | 624 | 28.1 | 49% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
3080 | 1890 | ANTISECRETORY FACTOR//LOTEPREDNOL ETABONATE//METADOXINE |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | LOTEPREDNOL ETABONATE | Author keyword | 31 | 76% | 4% | 22 |
2 | ANTEDRUG | Author keyword | 19 | 71% | 2% | 15 |
3 | CHEMICAL DELIVERY SYSTEM | Author keyword | 17 | 70% | 2% | 14 |
4 | ANTIINFLAMMATORY | Address | 13 | 80% | 1% | 8 |
5 | NBP ASSAY | Author keyword | 8 | 100% | 1% | 5 |
6 | BRAIN SPECIFIC DELIVERY | Author keyword | 6 | 80% | 1% | 4 |
7 | ANTEDRUGS | Author keyword | 6 | 100% | 1% | 4 |
8 | SOFT CORTICOSTEROID | Author keyword | 6 | 100% | 1% | 4 |
9 | SOFT DRUGS | Author keyword | 5 | 42% | 2% | 10 |
10 | CHEMICAL DELIVERY SYSTEMS | Author keyword | 5 | 50% | 1% | 7 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | LOTEPREDNOL ETABONATE | 31 | 76% | 4% | 22 | Search LOTEPREDNOL+ETABONATE | Search LOTEPREDNOL+ETABONATE |
2 | ANTEDRUG | 19 | 71% | 2% | 15 | Search ANTEDRUG | Search ANTEDRUG |
3 | CHEMICAL DELIVERY SYSTEM | 17 | 70% | 2% | 14 | Search CHEMICAL+DELIVERY+SYSTEM | Search CHEMICAL+DELIVERY+SYSTEM |
4 | NBP ASSAY | 8 | 100% | 1% | 5 | Search NBP+ASSAY | Search NBP+ASSAY |
5 | BRAIN SPECIFIC DELIVERY | 6 | 80% | 1% | 4 | Search BRAIN+SPECIFIC+DELIVERY | Search BRAIN+SPECIFIC+DELIVERY |
6 | ANTEDRUGS | 6 | 100% | 1% | 4 | Search ANTEDRUGS | Search ANTEDRUGS |
7 | SOFT CORTICOSTEROID | 6 | 100% | 1% | 4 | Search SOFT+CORTICOSTEROID | Search SOFT+CORTICOSTEROID |
8 | SOFT DRUGS | 5 | 42% | 2% | 10 | Search SOFT+DRUGS | Search SOFT+DRUGS |
9 | CHEMICAL DELIVERY SYSTEMS | 5 | 50% | 1% | 7 | Search CHEMICAL+DELIVERY+SYSTEMS | Search CHEMICAL+DELIVERY+SYSTEMS |
10 | PREDNISOLONE DERIVATIVE | 3 | 100% | 0% | 3 | Search PREDNISOLONE+DERIVATIVE | Search PREDNISOLONE+DERIVATIVE |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | SOFT DRUGS | 27 | 74% | 3% | 20 |
2 | STEROIDAL ANTIINFLAMMATORY ANTEDRUGS | 21 | 90% | 1% | 9 |
3 | LOTEPREDNOL ETABONATE | 16 | 45% | 4% | 27 |
4 | BRAIN SPECIFIC DELIVERY | 15 | 88% | 1% | 7 |
5 | DIRECTED DELIVERY | 11 | 100% | 1% | 6 |
6 | FLUOROMETHOLONE | 7 | 53% | 1% | 9 |
7 | TIME COURSE EVALUATION | 7 | 67% | 1% | 6 |
8 | CHEMICAL DELIVERY SYSTEMS | 6 | 38% | 2% | 13 |
9 | ETIPREDNOL DICLOACETATE BNP 166 | 6 | 100% | 1% | 4 |
10 | SOFT BETA BLOCKERS | 5 | 63% | 1% | 5 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Soft drug design: General principles and recent applications | 2000 | 95 | 138 | 51% |
Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems | 1999 | 81 | 100 | 55% |
Synthesis and Pharmacology of Anti-inflammatory Steroidal Antedrugs | 2008 | 19 | 80 | 86% |
Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems | 2005 | 30 | 69 | 55% |
Recent advances in retrometabolic drug design (RMDD) and development | 2010 | 7 | 48 | 60% |
Targeting drugs to the brain by redox chemical delivery systems | 2000 | 67 | 145 | 45% |
Corticosteroid design for the treatment of asthma: Structural insights and the therapeutic potential of soft corticosteroids | 2006 | 24 | 111 | 41% |
DRUG TARGETING AND RETROMETABOLIC DRUG DESIGN APPROACHES - INTRODUCTION | 1994 | 20 | 18 | 89% |
Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites | 2004 | 18 | 17 | 53% |
Antedrugs: An approach to safer drugs | 2005 | 9 | 51 | 78% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTIINFLAMMATORY | 13 | 80% | 1.3% | 8 |
2 | MOL CELLULAR PHARMACOL DIABET | 4 | 75% | 0.5% | 3 |
3 | ANTI INFLAMMATORY | 1 | 50% | 0.3% | 2 |
4 | TOKYO PHARMACEUT S | 1 | 50% | 0.2% | 1 |
5 | USTAV CHEM LEC | 1 | 50% | 0.2% | 1 |
6 | BIOCATALYSIS BIOTRANSFORMAT GRP | 0 | 33% | 0.2% | 1 |
7 | EUROPEAN PHARMACEUT CLIN SCI | 0 | 33% | 0.2% | 1 |
8 | L DESF | 0 | 33% | 0.2% | 1 |
9 | MED MIL MED | 0 | 33% | 0.2% | 1 |
10 | PLANEJAMENTO SINTESE QUIMIOTER ICOS POTENC | 0 | 33% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000104431 | DIFFUSION CELL EXPERIMENTS//TRANSFORMED POTTS GUY EQUATION//ROBERTS SLOAN EQUATION |
2 | 0.0000087633 | TIPREDANE//DITHIOKETAL//WILD QUAIL |
3 | 0.0000078944 | L DOPA PRODRUGS//6 HYDROXYDOPAMINE 6 OHDA LESIONED RAT//PROXIMAGEN NEUROSCI PLC |
4 | 0.0000070372 | MERBARONE//SEZ CHIM FARMACO PRODOTTO COSMET//SQUAMOUS CELL CARCINOMA CERVIX |
5 | 0.0000065430 | NEPAFENAC//TOPICAL ANESTHETIC ABUSE//BROMFENAC |
6 | 0.0000063290 | ALLERGIC CONJUNCTIVITIS//VERNAL KERATOCONJUNCTIVITIS//SEASONAL ALLERGIC CONJUNCTIVITIS |
7 | 0.0000059818 | PRONUCLEOTIDES//PROTIDE//PRONUCLEOTIDE |
8 | 0.0000056253 | TEARS OF THE NONPIGMENTED EPITHELIUM OF THE CILIARY BODY//CONJUNCTIVAL AND CORNEAL CALCIFICATION//CONJUNCTIVAL CALCIFICATION |
9 | 0.0000049351 | DEXANABINOL//HU 211//NONPSYCHOTROPIC CANNABINOIDS |
10 | 0.0000048127 | HUMAN SKIN BLANCHING ASSAY//SKIN BLANCHING//CLOBETASOL 17 PROPIONATE |